サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1782000

バイオシミラーと生物製剤市場：製品タイプ別、用途別、流通別、製造タイプ別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Biosimilar and Biologics Market, By Product Type, By Application, By Distribution, By Manufacturing Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
バイオシミラーと生物製剤市場：製品タイプ別、用途別、流通別、製造タイプ別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年07月04日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

バイオシミラーと生物製剤の市場規模は2024年に5,563億944万米ドルとなり、2025～2032年にかけてCAGR 7.81%で拡大

バイオシミラーと生物製剤市場-市場力学

大ヒット生物製剤の特許切れ

バイオシミラー市場の最も大きな成長促進要因の1つは、大型生物製剤の特許切れです。これらの生物製剤はしばしば「ブロックバスター」と呼ばれ、年間数十億の売上を生み出しています。特許が切れると、バイオシミラー医薬品メーカーがより安価な代替品を開発・販売する道が開かれます。例えば、関節リウマチやクローン病の治療として世界で最も売れている生物製剤のひとつであるアダリムマブ（ヒュミラ）は、バイオシミラーが市場に参入する以前は年間200億米ドル以上の売上をあげていました。ブロックバスター生物製剤の特許切れは、バイオシミラー市場成長の基本的な原動力です。競合を可能にし、薬価を引き下げ、生物製剤へのアクセスを拡大することで、最終的にはよりサステイナブル世界のヘルスケアシステムを構築することになります。この動向は、今後10年間でさらに多くの生物製剤が独占権を失い、バイオシミラー開発と採用が急増する道を開くことになります。

バイオシミラーと生物製剤市場-主要な洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2025～2032年）に約7.81%のCAGRで毎年成長すると推定されます。

製品タイプ別では、生物製剤が2024年に最大の市場シェアを示すと予測されています。

用途別では、2024年にはがん領域が主要用途となっています。

流通セグメント別では、病院薬局が2024年に主要流通となります。

地域別では、北米が2024年の売上高をリードしています。

バイオシミラーと生物製剤市場-セグメンテーション分析

バイオシミラーと生物製剤の世界市場は、製品タイプ、用途、流通、製造タイプ、地域によって区分されます。

市場は製品タイプによって2つに分類されます：生物製剤とバイオシミラーです。生物製剤は、がんや自己免疫疾患などの疾患の治療に使用される、生物から作られたオリジナルの複雑な医薬品です。バイオシミラーは、承認された生物製剤の高度に類似した廉価版で、先発品の特許が切れた後に開発され、同等の安全性と有効性を記載しています。

バイオシミラー市場は、用途によって2つのカテゴリーに分けられます：がん、感染症、自己免疫疾患（関節リウマチ、乾癬など）、血液疾患（貧血、血友病など）、糖尿病、成長ホルモン欠乏症、眼科疾患（黄斑変性症など）、その他（希少疾患、不妊治療など）です。がんは世界的に主要な死因の一つであり、高齢化、ライフスタイルの変化、診断法の改善により罹患率が上昇しています。生物製剤、特にモノクローナル抗体と標的療法は、従来型化学療法に比べて副作用が少なく、個別化された効果的な解決策を提供することで、がん治療に革命をもたらしました。さらに、生物製剤とバイオシミラーの研究開発投資、臨床検査、規制当局の承認において、がん領域が大きな割合を占めており、その優位性を強めています。がん患者の増加が予測され、精密医療への注目が高まる中、がん領域は今後もこの市場で最も需要が高く、収益性の高い用途セグメントであり続けると考えられます。

バイオシミラーと生物製剤市場-地理的洞察

バイオシミラーと生物製剤市場は、地理的地域によって成長パターンが異なります。北米、特に米国は、先進的ヘルスケアインフラ、強力な研究開発投資、主要製薬企業の存在により、生物製剤市場で大きなシェアを占めています。米国では当初、規制や市場の障壁からバイオシミラー医薬品の導入が遅れていたが、ヒュミラのようなブロックバスター医薬品の特許切れに伴い、導入が加速しています。欧州はバイオシミラーにとって最も成熟し確立された市場であり、コスト抑制施策、欧州の医薬品庁（EMA）による支援的な規制枠組み、医師や患者の高い受容性がその原動力となっています。アジア太平洋は最も急速に成長している地域で、インド、中国、韓国などの国々が主要なバイオシミラーメーカーとして台頭してきています。この成長を支えているのは、患者数の多さ、ヘルスケアへのアクセスの増加、規制の改善です。ラテンアメリカでは、各国が医療制度を近代化し、公共支出を削減するためにバイオシミラーの使用を奨励しているため、市場は順調に拡大しています。最後に、中東・アフリカは、アクセスとインフラ整備の課題は残るも、手頃な価格の生物製剤治療に対する需要が高まっている新興市場です。全体として、バイオシミラー医薬品の導入は欧州がリードしていますが、北米のとアジア太平洋が今後の市場成長を牽引することになると考えられます。

バイオシミラーと生物製剤市場-競合情勢

バイオシミラーと生物製剤市場の競合情勢は、大手製薬企業と新興バイオテクノロジー企業の競争間の敵対関係によって特徴付けられています。Amgen、Pfizer、Roche、Novartis（Sandoz）、Samsung Bioepis、Biocon、Celltrion、Mylan（Viatris）といった大手企業が市場を独占しており、強力な研究開発能力、広範な製造施設、世界の流通網を活用して市場シェアの維持・拡大を図っています。これらの企業は、特許が切れた、あるいは切れつつある需要の高い生物製剤のバイオシミラー開発に多額の投資を行っています。競合は価格だけでなく、製品の品質、規制当局の承認、特許戦略、医師や患者の信頼を築くためのマーケティング努力などにも基づいています。さらに、パイプラインポートフォリオを強化し、新たな市場に参入するための戦略的提携、共同研究、M&Aも一般的です。この情勢は、規制要件や市場アクセスの地域差によってさらに複雑化し、各社のバイオシミラー製品の世界の位置付けに影響を及ぼしています。市場が発展するにつれ、バイオプロセス技術やテーラーメイド治療におけるイノベーションは、この急成長セグメントで競合を維持しようとする企業にとって極めて重要になります。

目次

第1章 バイオシミラーと生物製剤市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 バイオシミラーと生物製剤の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 バイオシミラーと生物製剤産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 バイオシミラーと生物製剤市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 バイオシミラーと生物製剤市場情勢

  • バイオシミラーと生物製剤市場シェア分析、2024年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 バイオシミラーと生物製剤市場-製品タイプ別

  • 概要
    • 製品タイプ別セグメントシェア分析
    • 生物製剤
      • モノクローナル抗体（mAbs）
      • ワクチン
      • 組み換えホルモン（例：インスリン、ヒト成長ホルモン）
      • 治療用タンパク質（例：エリスロポエチン、インターフェロン）
      • 血液製品
      • 遺伝子治療
      • 細胞療法
    • バイオシミラー
      • モノクローナル抗体バイオシミラー
      • 組み換えホルモンバイオシミラー（例：インスリン、成長ホルモン）
      • エリスロポエチンバイオシミラー
      • フィルグラスチムとペグフィルグラスチムのバイオシミラー
      • インフリキシマブ、アダリムマブ、トラスツズマブのバイオシミラー
      • インターフェロンバイオシミラー

第8章 バイオシミラーと生物製剤市場-用途別

  • 概要
    • 用途別セグメントシェア分析
    • 腫瘍学
    • 感染症
    • 自己免疫疾患（例：関節リウマチ、乾癬）
    • 血液疾患（例：貧血、血友病）
    • 糖尿病
    • 成長ホルモン欠乏症
    • 眼疾患（例：黄斑変性）
    • その他（例：希少疾患、不妊治療）

第9章 バイオシミラーと生物製剤市場-流通別

  • 概要
    • 流通別セグメントシェア分析
    • 病院薬局
    • オンライン薬局
    • 小売薬局

第10章 バイオシミラーと生物製剤市場-製造タイプ別

  • 概要
    • 製造タイプ別セグメントシェア分析
    • 社内製造
    • 契約製造組織（CMO）

第11章 バイオシミラーと生物製剤市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析-バイオシミラーと生物製剤産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Amgen Inc.
    • Novartis AG（Sandoz）
    • Pfizer Inc.
    • Roche Holding AG
    • Samsung Bioepis
    • Biocon Ltd.
    • Mylan NV（Viatris）
    • Celltrion Inc.
    • Fresenius Kabi
    • Boehringer Ingelheim
    • Cipla Limited
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz（a Novartis division）
    • Dr. Reddy's Laboratories
    • Intas Pharmaceuticals Ltd.
    • Zhejiang Hisun Pharmaceutical Co., Ltd.
    • LG Chem Life Sciences
    • Pfizer Inc.
    • Hetero Drugs Limited
    • Oncobiologics, Inc.
    • その他

第13章 アナリストの全方位的展望

目次
Product Code: ANV5382

REPORT HIGHLIGHT

Biosimilar and Biologics Market size was valued at US$ 556,309.44 Million in 2024, expanding at a CAGR of 7.81% from 2025 to 2032.

The biosimilars and biologics market represents one of the fastest-growing sectors in the global pharmaceutical industry. Biologics are large, complex molecules or mixtures of molecules derived from living cells used in the treatment, diagnosis, or prevention of diseases. Examples include monoclonal antibodies, vaccines, and recombinant proteins. Fueled by advances in biotechnology, rising prevalence of chronic diseases, patent expirations of blockbuster biologics, and increasing healthcare costs, the market is witnessing rapid transformation.

Biosimilar and Biologics Market- Market Dynamics

Patent Expiration of Blockbuster Biologics

One of the most significant growth drivers in the biosimilars market is the expiration of patents for major biologic drugs. These biologics, often called "blockbusters", generate billions in annual sales. When their patents expire, it opens the door for biosimilar manufacturers to develop and market more affordable alternatives. For instance, Adalimumab (Humira), one of the world's top-selling biologics used to treat rheumatoid arthritis and Crohn's disease, generated over $20 billion/year in revenue before biosimilars entered the market. The expiration of patents on blockbuster biologics is a fundamental driver of growth in the biosimilar market. It enables competition, reduces drug prices, and expands access to biologic therapies-ultimately creating a more sustainable global healthcare system. This trend will continue over the next decade as more biologics lose exclusivity, paving the way for a surge in biosimilar development and adoption.

Biosimilar and Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.81% over the forecast period (2025-2032)

Based on product type segmentation, Biologics was predicted to show maximum market share in the year 2024

Based on application segmentation, Oncology was the leading application in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Biosimilar and Biologics Market- Segmentation Analysis:

The Global Biosimilar and Biologics Market is segmented on the basis of Product Type, Application, Distribution, Manufacturing Type, and Region.

The market is divided into two categories based on product type: Biologics, and Biosimilars. Biologics and Biosimilars. Biologics are original, complex medicines made from living organisms, used to treat diseases like cancer and autoimmune disorders. Biosimilars are highly similar, lower-cost versions of approved biologics, developed after the original product's patent expires, offering comparable safety and effectiveness.

The market is divided into two categories based on application: Oncology, Infectious Diseases, Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis), Blood Disorders (e.g., anemia, hemophilia), Diabetes, Growth Hormone Deficiency, Ophthalmic Disorders (e.g., macular degeneration) and Others (e.g., rare diseases, fertility treatments). Cancer is one of the leading causes of death globally, with a rising incidence due to aging populations, lifestyle changes, and improved diagnostics. Biologics particularly monoclonal antibodies and targeted therapies-have revolutionized cancer treatment by offering personalized, effective solutions with fewer side effects compared to traditional chemotherapy. Additionally, oncology accounts for a large share of R&D investments, clinical trials, and regulatory approvals in both biologics and biosimilars, reinforcing its dominance. With cancer cases projected to rise and the focus on precision medicine growing, oncology will likely remain the most demanding and profitable application area in this market.

Biosimilar and Biologics Market- Geographical Insights

The biosimilar and biologics market shows varying growth patterns across different geographical regions. North America, particularly the United States, holds a major share in the biologics market due to advanced healthcare infrastructure, strong R&D investments, and the presence of key pharmaceutical players. Although biosimilar adoption was initially slow in the U.S. due to regulatory and market barriers, it is now accelerating following the expiration of patents for blockbuster drugs like Humira. Europe is the most mature and established market for biosimilars, driven by cost-containment policies, supportive regulatory frameworks by the European Medicines Agency (EMA), and high physician and patient acceptance. Asia-Pacific is the fastest-growing region, with countries like India, China, and South Korea emerging as major biosimilar manufacturers. This growth is supported by large patient populations, increasing healthcare access, and improving regulatory pathways. In Latin America, the market is expanding steadily as countries modernize their healthcare systems and encourage biosimilar use to reduce public spending. Lastly, the Middle East and Africa represent emerging markets with growing demand for affordable biologic treatments, although access and infrastructure challenges remain. Overall, while Europe leads in biosimilar adoption, North America and Asia-Pacific are set to drive future market growth.

Biosimilar and Biologics Market- Competitive Landscape:

The competitive landscape of the biosimilars and biologics market is characterized by intense rivalry among a mix of established pharmaceutical giants and emerging biotech companies. Major players like Amgen, Pfizer, Roche, Novartis (Sandoz), Samsung Bioepis, Biocon, Celltrion, and Mylan (Viatris) dominate the market, leveraging strong R&D capabilities, extensive manufacturing facilities, and global distribution networks to maintain and expand their market share. These companies are investing heavily in developing biosimilars for high-demand biologics whose patents have expired or are nearing expiration. Competition is not only based on pricing but also on product quality, regulatory approvals, patent strategies, and marketing efforts to build physician and patient trust. Additionally, strategic partnerships, collaborations, and mergers and acquisitions are common to enhance pipeline portfolios and access new markets. The landscape is further complicated by regional differences in regulatory requirements and market access, which influence how companies position their biosimilar products worldwide. As the market evolves, innovation in bioprocessing technologies and tailored therapies will be crucial for companies aiming to stay competitive in this rapidly growing sector.

Recent Developments:

In March 2025, Fresenius Kabi received U.S. FDA approval for two of their denosumab biosimilars, Conexxence and Bomyntra, which are now approved for the same indications as the original reference drugs, Prolia and Xgeva, respectively. This approval enhances treatment options for patients with osteoporosis and cancer-related bone loss, contributing to the growing acceptance of biosimilars in the U.S. market .

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Bioepis
  • Biocon Ltd.
  • Mylan N.V. (Viatris)
  • Celltrion Inc.
  • Fresenius Kabi
  • Boehringer Ingelheim
  • Cipla Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz (a Novartis division)
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • LG Chem Life Sciences
  • Pfizer Inc.
  • Hetero Drugs Limited
  • Oncobiologics, Inc.
  • Others

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Biologics:

  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Recombinant Hormones (e.g., insulin, human growth hormone)
  • Therapeutic Proteins (e.g., erythropoietin, interferons)
  • Blood Products
  • Gene Therapy
  • Cell Therapy

Biosimilars:

  • Monoclonal Antibodies Biosimilars
  • Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
  • Erythropoietin Biosimilars
  • Filgrastim and Pegfilgrastim Biosimilars
  • Infliximab, Adalimumab, Trastuzumab Biosimilars
  • Interferons Biosimilars

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Infectious Diseases
  • Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
  • Blood Disorders (e.g., anemia, hemophilia)
  • Diabetes
  • Growth Hormone Deficiency
  • Ophthalmic Disorders (e.g., macular degeneration)
  • Others (e.g., rare diseases, fertility treatments)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY MANUFACTURING TYPE- MARKET ANALYSIS, 2019 - 2032

  • In-house Manufacturing
  • Contract Manufacturing Organizations (CMOs)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biosimilar and Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilar and Biologics Market Snippet by Product Type
    • 2.1.2. Biosimilar and Biologics Market Snippet by Application
    • 2.1.3. Biosimilar and Biologics Market Snippet by Distribution
    • 2.1.4. Biosimilar and Biologics Market Snippet by Manufacturing Type
    • 2.1.5. Biosimilar and Biologics Market Snippet by Country
    • 2.1.6. Biosimilar and Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilar and Biologics Key Market Trends

  • 3.1. Biosimilar and Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilar and Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilar and Biologics Market Opportunities
  • 3.4. Biosimilar and Biologics Market Future Trends

4. Biosimilar and Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilar and Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biosimilar and Biologics Market Landscape

  • 6.1. Biosimilar and Biologics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilar and Biologics Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Biologics:
      • 7.1.2.1. Monoclonal Antibodies (mAbs)
      • 7.1.2.2. Vaccines
      • 7.1.2.3. Recombinant Hormones (e.g., insulin, human growth hormone)
      • 7.1.2.4. Therapeutic Proteins (e.g., erythropoietin, interferons)
      • 7.1.2.5. Blood Products
      • 7.1.2.6. Gene Therapy
      • 7.1.2.7. Cell Therapy
    • 7.1.3. Biosimilars:
      • 7.1.3.1. Monoclonal Antibodies Biosimilars
      • 7.1.3.2. Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
      • 7.1.3.3. Erythropoietin Biosimilars
      • 7.1.3.4. Filgrastim and Pegfilgrastim Biosimilars
      • 7.1.3.5. Infliximab, Adalimumab, Trastuzumab Biosimilars
      • 7.1.3.6. Interferons Biosimilars

8. Biosimilar and Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Infectious Diseases
    • 8.1.4. Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
    • 8.1.5. Blood Disorders (e.g., anemia, hemophilia)
    • 8.1.6. Diabetes
    • 8.1.7. Growth Hormone Deficiency
    • 8.1.8. Ophthalmic Disorders (e.g., macular degeneration)
    • 8.1.9. Others (e.g., rare diseases, fertility treatments)

9. Biosimilar and Biologics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Biosimilar and Biologics Market - By Manufacturing Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Manufacturing Type, 2024 & 2032 (%)
    • 10.1.2. In-house Manufacturing
    • 10.1.3. Contract Manufacturing Organizations (CMOs)

11. Biosimilar and Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Biosimilar and Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Biosimilar and Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Biosimilar and Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Biosimilar and Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Biosimilar and Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Biosimilar and Biologics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Novartis AG (Sandoz)
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Roche Holding AG
    • 12.2.5. Samsung Bioepis
    • 12.2.6. Biocon Ltd.
    • 12.2.7. Mylan N.V. (Viatris)
    • 12.2.8. Celltrion Inc.
    • 12.2.9. Fresenius Kabi
    • 12.2.10. Boehringer Ingelheim
    • 12.2.11. Cipla Limited
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Sandoz (a Novartis division)
    • 12.2.14. Dr. Reddy's Laboratories
    • 12.2.15. Intas Pharmaceuticals Ltd.
    • 12.2.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 12.2.17. LG Chem Life Sciences
    • 12.2.18. Pfizer Inc.
    • 12.2.19. Hetero Drugs Limited
    • 12.2.20. Oncobiologics, Inc.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us